Huons Global
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Huons Global is the holding company, a parent entity that controls other businesses by owning their shares, for the Huons Group, a Korean health-care conglomerate listed on KOSDAQ.
Its main subsidiaries manufacture and supply prescription medicines (including local anaesthetics and eye drops), wellness injectables, and weight-management drugs to hospitals, clinics, and pharmacies in Korea, and also produce pharmaceuticals on a contract basis for other domestic and international drug companies. As a pure holding company, Huons Global's own revenues come primarily from trademark-licensing fees, management-advisory fees, dividends from subsidiaries, and rental income.
Summary is AI-generated and may contain errors · figures from DART filings
Huons Global operates as a pure holding company after spinning off its bio-pharmaceutical operations into a separate subsidiary, Huons Biopharma Co., Ltd., leaving it with no direct manufacturing activities of its own.
Huons Global in five facts
What does Huons Global do?
Huons Global is the holding company, a parent entity that controls other businesses by owning their shares, for the Huons Group, a Korean health-care conglomerate listed on KOSDAQ.
Where is Huons Global listed and in which sector?
Huons Global (Korean name: 휴온스글로벌) trades under KRX code 084110 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Huons Global?
Its market capitalisation was US$203.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Huons Global's latest annual revenue and operating profit?
For fiscal year 2025, Huons Global reported revenue of US$639.6M, operating profit of US$68.3M and net income of US$61.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 4.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 21
- DisclosureSep 23
- [Amended] Matter subject to ad-hoc disclosure (fair disclosure)
Huons Global withdrew its June 8, 2026 plan to pay an in-kind dividend of newly issued Huons shares (about 260,000 of the roughly 2,204,297 merger shares it was to receive) to minority shareholders, after the underlying subsidiary merger that the dividend plan depended on was itself withdrawn.
Dividend · Aug 26 - [Amended] Material event report (merger) (subsidiary)
Huons Co., Ltd. terminated its merger agreement with Huons Lab Co., Ltd. and withdrew the May 18, 2026 merger decision on August 26, 2026, canceling all related procedures including the shareholders' meeting, citing shareholder opposition, a new duplicate-listing guideline, and a widening gap between the original merger valuation/appraisal price and the current share price amid pharma-sector volatility.
M&A · Aug 26 - Cash/in-kind dividend decision (subsidiary) (quarterly dividend)
Huons Co., Ltd., a subsidiary of Huons Global, declared a quarterly cash dividend of US$0.14 per common share (total US$1.65M), with a record date of 2026-08-31 and payment expected 2026-09-16.
Dividend · Aug 11 - Cash/in-kind dividend decision (quarterly dividend)
Huons Global declared a cash dividend of US$0.28 per share, equal to about 1.59% of the recent share price.
Dividend · Aug 11 - [Amended] Material event report (merger) (subsidiary)
Huons Co., Ltd. (subsidiary of Huons Global) amends its May 18, 2026 report on absorbing Huons Lab Co., Ltd. by merger at a ratio of 1:0.4256943, postponing the merger schedule (shareholders' meeting, appraisal-rights period, merger date, new-share listing, etc.) to allow time for parent-company compliance procedures under the dual-listing guideline; as of the August 4, 2026 amendment the revised dates are not yet fixed, while the merger ratio and other original terms are unchanged.
M&A · Aug 4 · 5 versions - Matter subject to ad-hoc disclosure (fair disclosure)Dividend · Jun 8
- Cash/in-kind dividend decision (subsidiary)Dividend · May 12
- Cash/in-kind dividend decision
Huons Global declared a cash dividend of US$0.13 per share, equal to about 0.34% of the recent share price.
Dividend · May 12 - [Attachment amended] Material event report (merger) (subsidiary)M&A · Apr 23
- Material event report (merger) (subsidiary)M&A · Apr 22
- [Amended] Cash/in-kind dividend decision
Huons Global updated its declared cash dividend of US$0.14 per share, equal to about 0.39% of the recent share price.
Dividend · Apr 13 · 2 versions - Change of less than 30% in revenue or profit/loss structure (15% for large companies) (voluntary)
Huons Global reported consolidated results for FY2025: revenue of US$588M (+4.2% year on year), operating profit of US$62.9M (−6.6% year on year) and net income of US$56M (+20.2% year on year).
Earnings · Feb 13 - Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
Huons Global reported a subsidiary's consolidated results for FY2025: revenue of US$431M (+5.2% year on year), operating profit of US$31.7M (+14.9% year on year) and net income of US$28.9M (+43.2% year on year).
Earnings · Feb 13 - Cash/in-kind dividend decision (subsidiary)Dividend · Feb 13